Evidence map›Paper›PMID 37375845›Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

Pharmacological Approaches to Modulate the Scarring Process after Glaucoma Surgery.

Debora Collotta, Simona Colletta, Virginia Carlucci, Claudia Fruttero, Antonio Maria Fea, Massimo Collino

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Wound Modulations in Glaucoma Surgery: A Systematic Review.Bioengineering (Basel, Switzerland) · 2024
    Review
  7. Article
  8. Immunomodulatory and Antioxidant Drugs in Glaucoma Treatment.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  9. Use of Mitomycin C in Ophthalmic Surgery.Journal of current ophthalmology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Debora CollottaDepartment of Neurosciences "Rita Levi Montalcini", University of Turin, 10126 Turin, Italy.ORCID 0000-0002-5569-7509
Simona CollettaDepartment of Neurosciences "Rita Levi Montalcini", University of Turin, 10126 Turin, Italy.ORCID 0000-0002-7244-2065
Virginia CarlucciChemsafe S.r.l., Via Ribes 5, 10010 Colleretto Giacosa, Italy.ORCID 0000-0003-0764-0206
Claudia FrutteroHospital Pharmacy, S. Croce e Carle Hospital Cuneo, 12100 Cuneo, Italy.
Antonio Maria FeaStruttura Complessa Oculistica, Città Della Salute e Della Scienza di Torino, Dipartimento di Scienze Chirurgiche, Università degli Studi di Torino, 10126 Torino, Italy.
Massimo CollinoDepartment of Neurosciences "Rita Levi Montalcini", University of Turin, 10126 Turin, Italy.ORCID 0000-0001-8782-3496
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glaucoma is an acquired optic neuropathy that results in a characteristic optic nerve head appearance and visual field loss. Reducing the IOP is the only factor that can be modified, and the progression of the disease can be managed through medication, laser treatment, or surgery. Filtering procedures are used when target pressure cannot be obtained with less invasive methods. Nevertheless, these procedures require accurate control of the fibrotic process, which can hamper filtration, thus, negatively affecting the surgical success. This review explores the available and potential pharmacological treatments that modulate the scarring process after glaucoma surgery, analyzing the most critical evidence available in the literature. The modulation of scarring is based on non-steroidal anti-inflammatory drugs (NSAIDs), mitomycin, and 5-fluorouracil. In the long term, the failure rate of filtering surgery is mainly due to the limitations of the current strategies caused by the complexity of the fibrotic process and the pharmacological and toxicological aspects of the drugs that are currently in use. Considering these limitations, new potential treatments were investigated. This review suggests that a better approach to tackle the fibrotic process may be to hit multiple targets, thus increasing the inhibitory potential against excessive scarring following surgery.

Indexed as

fibrosisglaucomaglaucoma surgeryintraocular pressure

Identifiers

PMID37375845
PMCPMC10305204
OpenAlexW4381433490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.